Bausch & Lomb IPO to be one of 2013's largest
This article was originally published in Scrip
Bausch & Lomb entertained acquisition offers, but has decided to pursue an initial public offering instead - a strategy in line with CEO Brent Saunders' assertion in January that the ophthalmology company likely would return to the public markets.
You may also be interested in...
Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.